BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Moderna Leans into R&D as Spikevax Sales Face Drop-Off

  Riding high on Spikevax sales, Moderna closed out 2022 with strong financials and a plan to invest heavily into R&D in 2023.

  February 23, 2023

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Deals

  Jounce Slashes 57% of Staff, Drops Assets in Stock Merger with Redx

  One day after revealing a restructuring initiative, Jounce Therapeutics announced it plans to merge its business in an all-stock deal with clinical-stage biotech Redx Pharma.

  February 23, 2023

   · 

  1 min read

   · 

  Rosemary Scott
• 

  Drug Development

  Graphite Bio Cuts Sickle Cell Therapy, Half of Staff

  Graphite Bio is discontinuing the development of nulabeglogene autogedtemcel (nula-cel), its lead asset, and shaving off about 50% of its workforce.

  February 23, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Novartis Drops SCD Gene Therapy Program with Intellia

  Novartis has abandoned its ex vivo sickle cell disease program developed using Intellia Therapeutics’ CRISPR gene editing platform, Intellia announced Thursday.

  February 23, 2023

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Business

  AbbVie, Capsida Set Sights on Gene Therapies for Eye Diseases

  With more than $600 million on the line, AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics to advance three gene therapy programs for eye diseases.

  February 23, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• Genetown

  Biophytis To Host a Combined General Shareholder’s Meeting on March 30, 2023

  Biophytis SA announced it is convening an Extraordinary and Ordinary Shareholders’ Meeting for March 30, 2023.

  February 23, 2023

   · 

  3 min read
• Business

  Immunovia Publishes Full Year Report for 2022

  In Q4, Immunovia continued to execute on its unique position as a leader in innovative early detection of pancreatic cancer.

  February 23, 2023

   · 

  10 min read
• Medivir to present at the Erik Penser Bank Healthcare Day - February 23, 2023

  Medivir AB announces that the company will present at the Erik Penser Bank Healthcare Day today, February 23, 2023.

  February 23, 2023

   · 

  1 min read
• Pharm Country

  AtlantiCare First in Northeast to Deploy Optellum AI Alongside Robotics for Early Lung Cancer Diagnosis and Treatment

  AtlantiCare is the first healthcare system in the northeastern U.S. to use Optellum’s Virtual Nodule Clinic.

  February 23, 2023

   · 

  5 min read
• AviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology

  AviadoBio and Neurgain Technologies, Inc. announced that the companies have entered into an exclusive license and collaboration agreement on an investigational novel subpial delivery technology for gene therapies targeting neurological diseases with spinal cord involvement.

  February 23, 2023

   · 

  4 min read